当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Vitamin D receptor expression in invasive breast tumors and breast cancer survival.

Vitamin D receptor expression in invasive breast tumors and breast cancer survival.

Abstract：

BACKGROUND:Vitamin D has been suggested to prevent and improve the prognosis of several cancers, including breast cancer. We have previously shown a U-shaped association between pre-diagnostic serum levels of vitamin D and risk of breast cancer-related death, with poor survival in patients with the lowest and the highest levels respectively, as compared to the intermediate group. Vitamin D exerts its functions through the vitamin D receptor (VDR), and the aim of the current study was to investigate if the expression of VDR in invasive breast tumors is associated with breast cancer prognosis. METHODS:VDR expression was evaluated in a tissue microarray of 718 invasive breast tumors. Covariation between VDR expression and established prognostic factors for breast cancer was analyzed, as well as associations between VDR expression and breast cancer mortality. RESULTS:We found that positive VDR expression in the nuclei and cytoplasm of breast cancer cells was associated with favorable tumor characteristics such as smaller size, lower grade, estrogen receptor positivity and progesterone receptor positivity, and lower expression of Ki67. In addition, both intranuclear and cytoplasmic VDR expression were associated with a low risk of breast cancer mortality, hazard ratios 0.56 (95% CI 0.34-0.91) and 0.59 (0.30-1.16) respectively. CONCLUSIONS:This study found that high expression of VDR in invasive breast tumors is associated with favorable prognostic factors and a low risk of breast cancer death. Hence, a high VDR expression is a positive prognostic factor.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Huss L,Butt ST,Borgquist S,Elebro K,Sandsveden M,Rosendahl A,Manjer J

doi

10.1186/s13058-019-1169-1

subject

Has Abstract

pub_date

2019-07-29 00:00:00

pages

84

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-019-1169-1

journal_volume

21

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH文献大全
  • Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

    abstract：:Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit DNA repair deficien...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2566

    authors： Rowe BP,Glazer PM

    更新日期：2010-01-01 00:00:00

  • Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda.

    abstract：:Many women newly diagnosed with breast cancer and with a strong family history of breast cancer are referred to a family cancer service for genetic counselling and for consideration of genetic testing for germline mutations in cancer predisposition genes following completion of their cancer treatment. However, there i...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2194

    authors： Meiser B,Tucker K,Friedlander M,Barlow-Stewart K,Lobb E,Saunders C,Mitchell G

    更新日期：2008-01-01 00:00:00

  • Addition of T2-guided optical tomography improves noncontrast breast magnetic resonance imaging diagnosis.

    abstract：BACKGROUND:While dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) is recognized as the most sensitive examination for breast cancer detection, it has a substantial false positive rate and gadolinium (Gd) contrast agents are not universally well tolerated. As a result, alternatives to diagnosing breast can...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0902-x

    authors： Feng J,Xu J,Jiang S,Yin H,Zhao Y,Gui J,Wang K,Lv X,Ren F,Pogue BW,Paulsen KD

    更新日期：2017-10-24 00:00:00

  • The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.

    abstract：INTRODUCTION:AIB1, located at 20q12, is a member of the steroid hormone coactivator family. It contains a glutamine repeat (CAG/CAA) polymorphism at its carboxyl-terminal region that may alter the transcriptional activation of the receptor and affect susceptibility to breast cancer through altered sensitivity to hormon...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1009

    authors： Montgomery KG,Chang JH,Gertig DM,Dite GS,McCredie MR,Giles GG,Southey MC,Hopper JL,Campbell IG

    更新日期：2005-01-01 00:00:00

  • Approaches towards expression profiling the response to treatment.

    abstract：:Over the past 8 years there has been a wealth of breast cancer gene expression studies. The majority of these studies have focused upon characterising a tumour at presentation, before treatment, rather than looking at the effects of treatment on the tumour. More recently, a number of groups have moved from predicting ...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,社论

    doi：10.1186/bcr2196

    authors： Sims AH,Bartlett JM

    更新日期：2008-01-01 00:00:00

  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

    abstract：INTRODUCTION:Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondria...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0567-2

    authors： Blein S,Bardel C,Danjean V,McGuffog L,Healey S,Barrowdale D,Lee A,Dennis J,Kuchenbaecker KB,Soucy P,Terry MB,Chung WK,Goldgar DE,Buys SS,Breast Cancer Family Registry.,Janavicius R,Tihomirova L,Tung N,Dorfling CM,va

    更新日期：2015-04-25 00:00:00

  • Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.

    abstract：:ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and neuronal origin, in which they are involved in the control of diverse biological processes such as proliferation, differentiation, migration and apoptosis. Furthermore, their deregulated expression has been implicated in m...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr327

    authors： Olayioye MA

    更新日期：2001-01-01 00:00:00

  • A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

    abstract：BACKGROUND:Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from local recurrence. Although a mastectomy or adjuvant radiation can reduce recurrence risk, there are sig...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1165-5

    authors： Klimov S,Miligy IM,Gertych A,Jiang Y,Toss MS,Rida P,Ellis IO,Green A,Krishnamurti U,Rakha EA,Aneja R

    更新日期：2019-07-29 00:00:00

  • Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.

    abstract：INTRODUCTION:Despite advances in early detection and adjuvant targeted therapies, breast cancer is still the second most common cause of cancer mortality among women. Tumor recurrence is one of the major contributors to breast cancer mortality. However, the mechanisms underlying this process are not completely understo...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0649-1

    authors： Holdman XB,Welte T,Rajapakshe K,Pond A,Coarfa C,Mo Q,Huang S,Hilsenbeck SG,Edwards DP,Zhang X,Rosen JM

    更新日期：2015-11-18 00:00:00

  • Targeted therapies in breast cancer: are heart and vessels also being targeted?

    abstract：:The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of car...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr3142

    authors： Criscitiello C,Metzger-Filho O,Saini KS,de Castro G Jr,Diaz M,La Gerche A,de Azambuja E,Piccart-Gebhart MJ

    更新日期：2012-06-19 00:00:00

  • Hormonal control of p53 and chemoprevention.

    abstract：:Improvements in the detection and treatment of breast cancer have dramatically altered its clinical course and outcome. However, prevention of breast cancer remains an elusive goal. Parity, age of menarche, and age at menopause are major risk factors drawing attention to the important role of the endocrine system in d...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr431

    authors： Jerry DJ,Minter LM,Becker KA,Blackburn AC

    更新日期：2002-01-01 00:00:00

  • Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A.

    abstract：INTRODUCTION:This study was designed to determine if and how a non-toxic, naturally occurring bioflavonoid, galangin, affects proliferation of human mammary tumor cells. Our previous studies demonstrated that, in other cell types, galangin is a potent inhibitor of the aryl hydrocarbon receptor (AhR), an environmental c...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1391

    authors： Murray TJ,Yang X,Sherr DH

    更新日期：2006-01-01 00:00:00

  • Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

    abstract：:Zoledronic acid (ZA) is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free surv...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr3223

    authors： Steinman RA,Brufsky AM,Oesterreich S

    更新日期：2012-09-21 00:00:00

  • Adolescent diet and risk of breast cancer.

    abstract：BACKGROUND:Early life exposures, including diet, have been implicated in the etiology of breast cancer. METHODS:A nested case-control study was conducted among participants in the Nurses' Health Study who completed a 24-item questionnaire about diet during high school. There were 843 eligible cases diagnosed between o...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr583

    authors： Frazier AL,Ryan CT,Rockett H,Willett WC,Colditz GA

    更新日期：2003-01-01 00:00:00

  • Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib

    abstract：INTRODUCTION:Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations a...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0405-y

    authors： Xu B,Guan Z,Shen Z,Tong Z,Jiang Z,Yang J,DeSilvio M,Russo M,Leigh M,Ellis C

    更新日期：2014-07-24 00:00:00

  • RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation.

    abstract：INTRODUCTION:In response to gamma-irradiation (IR)-induced double-strand DNA breaks, cells undergo cell-cycle arrest, allowing time for DNA repair before reentering the cell cycle. G2/M checkpoint activation involves activation of ataxia telangiectasia mutated (ATM)/ATM- and rad3-related (ATR) kinases and inhibition of...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3164

    authors： Yan Y,Greer PM,Cao PT,Kolb RH,Cowan KH

    更新日期：2012-04-11 00:00:00

  • Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

    abstract：INTRODUCTION:Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2903

    authors： Kodera Y,Katanasaka Y,Kitamura Y,Tsuda H,Nishio K,Tamura T,Koizumi F

    更新日期：2011-06-21 00:00:00

  • Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage.

    abstract：:Estrogen-mediated proliferation is fundamental to normal mammary gland development. Recent studies have demonstrated that amphiregulin is a critical paracrine regulator of estrogen action during ductal morphogenesis. These studies implicate a critical role for amphiregulin in mammary stem cell differentiation as well ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1740

    authors： LaMarca HL,Rosen JM

    更新日期：2007-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract：BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1128-x

    authors： Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期：2019-03-28 00:00:00

  • More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.

    abstract：:Estrogen receptor α (ER) is a major driver of breast cancer and the target of endocrine therapy. Full disclosure of the cofactors regulating ER interactions with chromatin and its transcriptional regulatory activity is still elusive. Novel genome-wide profiling tools have mapped ER binding events in breast cancer cell...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2849

    authors： Fu X,Huang C,Schiff R

    更新日期：2011-04-20 00:00:00

  • Dendritic cell defects in patients with cancer: mechanisms and significance.

    abstract：:Dendritic cells (DCs) are a complex network of antigen-presenting cells that have an essential role in the modulation of primary immunity. There has been increasing evidence that DCs isolated from patients with malignancy demonstrate functional deficiencies that inhibit the capacity to mount an effective anti-tumor re...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章

    doi：10.1186/bcr1375

    authors： Lenahan C,Avigan D

    更新日期：2006-01-01 00:00:00

  • Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

    abstract：INTRODUCTION:Bisphosphonates have become standard therapy for the treatment of skeletal complications related to breast cancer. Although their therapeutic effects mainly result from an inhibition of osteoclastic bone resorption, in vitro data indicate that they also act directly on breast cancer cells, inhibiting proli...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1845

    authors： Journé F,Kheddoumi N,Chaboteaux C,Duvillier H,Laurent G,Body JJ

    更新日期：2008-01-01 00:00:00

  • CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.

    abstract：INTRODUCTION:Breast tumors are comprised of distinct cancer cell populations which differ in their tumorigenic and metastatic capacity. Characterization of cell surface markers enables investigators to distinguish between cancer stem cells and their counterparts. CD24 is a well-known cell surface marker for mammary epi...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0589-9

    authors： Rostoker R,Abelson S,Genkin I,Ben-Shmuel S,Sachidanandam R,Scheinman EJ,Bitton-Worms K,Orr ZS,Caspi A,Tzukerman M,LeRoith D

    更新日期：2015-06-04 00:00:00

  • Molecular drivers of lobular carcinoma in situ.

    abstract：:Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive breast carcinoma, but it may also be a non-obligate precursor to invasive lobular carcinoma (ILC). Many LCIS lesions do not progress to ILC, and the molecular changes that are necessary for progression from LCIS to ILC a...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/s13058-015-0580-5

    authors： Logan GJ,Dabbs DJ,Lucas PC,Jankowitz RC,Brown DD,Clark BZ,Oesterreich S,McAuliffe PF

    更新日期：2015-06-04 00:00:00

  • Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

    abstract：INTRODUCTION:The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects the cell of origin of these tumors. However, approximately 20% of breast cancers that de...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2776

    authors： Tung N,Miron A,Schnitt SJ,Gautam S,Fetten K,Kaplan J,Yassin Y,Buraimoh A,Kim JY,Szász AM,Tian R,Wang ZC,Collins LC,Brock J,Krag K,Legare RD,Sgroi D,Ryan PD,Silver DP,Garber JE,Richardson AL

    更新日期：2010-01-01 00:00:00

  • Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.

    abstract：BACKGROUND:Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resistance in tyrosine amino...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01367-7

    authors： Lee KM,Lee H,Han D,Moon WK,Kim K,Oh HJ,Choi J,Hwang EH,Kang SE,Im SA,Lee KH,Ryu HS

    更新日期：2020-11-25 00:00:00

  • Roles of BCCIP deficiency in mammary tumorigenesis.

    abstract：BACKGROUND:Dysregulated DNA repair and cell proliferation controls are essential driving forces in mammary tumorigenesis. BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The aims of t...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0907-5

    authors： Droz-Rosario R,Lu H,Liu J,Liu NA,Ganesan S,Xia B,Haffty BG,Shen Z

    更新日期：2017-10-18 00:00:00

  • HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.

    abstract：BACKGROUND:Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth factor receptor 2 (HER2) expression on CTCs and tdEVs of metastatic breast cancer patients. METHODS:B...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01323-5

    authors： Nanou A,Zeune LL,Bidard FC,Pierga JY,Terstappen LWMM

    更新日期：2020-08-12 00:00:00

  • Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator.

    abstract：INTRODUCTION:Activated leukocyte cell adhesion molecule (ALCAM) (CD166) is an immunoglobulin molecule that has been implicated in cell migration. The present study examined the expression of ALCAM in human breast cancer and assessed its prognostic value. METHODS:The immunohistochemical distribution and location of ALC...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr815

    authors： King JA,Ofori-Acquah SF,Stevens T,Al-Mehdi AB,Fodstad O,Jiang WG

    更新日期：2004-01-01 00:00:00

  • On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.

    abstract：:The increasing importance of signal transducer and activator of transcription 3 (STAT3) expression in human cancers has led several laboratories to examine in detail the expression of one of its major negative regulators in oncogenesis--the T-cell protein tyrosine phosphatase, nonreceptor type 2 (PTPN2). A recent pape...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章,评审

    doi：10.1186/bcr3437

    authors： Tremblay ML

    更新日期：2013-07-31 00:00:00